此延伸研究的目的是為持續耐受並從接受venetoclax中獲益的受試者提供venetoclax，並獲取長期安全性數據。
適應症：Chronic Lymphocytic Leukemia、Acute Myeloid Leukemia、Multiple Myeloma、Non-Hodgkin's Lymphoma、Acute Lymphoblastic Leukemia、Cancer
收案條件
納入條件
- Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug.
- Male subject agrees to refrain from sperm donation.
- Female subjects must not be pregnant or breastfeeding.
排除條件
- \- None.
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。